Action Exscientia - EXAI

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

4,84

Prix Achat

5,61

Prix Vente

4,55

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

4,84

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Form 15-12G - Securities registration termination [Section 12(g)]

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

EXAI - Frequently Asked Questions (FAQ)

What is the current Exscientia share price?

The current share price of Exscientia is US$ 4,84

What is the 1 year trading range for Exscientia share price?

Exscientia has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
RETOReTo Eco Solutions Inc	US$ 0,8101 (101,02%)	2,12M
GSUNGolden Sun Health Technology Group Ltd	US$ 4,49 (69,43%)	306,56k
SPGCSacks Parente Golf Inc	US$ 0,9472 (45,50%)	1,16M
ZYBTZhengye Biotechnology Holding Ltd	US$ 5,42 (17,32%)	39,03k
CNCKCoincheck Group NV	US$ 7,2957 (15,29%)	142
BOXLBoxlight Corporation	US$ 2,45 (-21,22%)	197,4k
STECSantech Holdings Limited	US$ 0,5901 (-9,26%)	1,57k
UPCUniverse Pharmaceuticals Inc	US$ 0,1845 (-7,89%)	813,39k
ZBAOZhibao Technology Inc	US$ 1,44 (-7,69%)	2,17k
NKGNNKGen Biotech Inc	US$ 0,5199 (-7,64%)	258,85k
DGLYDigital Ally Inc	US$ 0,0845 (2,30%)	3,17M
NVDANVIDIA Corporation	US$ 134,15 (-0,09%)	2,99M
TLRYTilray Brands Inc	US$ 0,8902 (-3,14%)	2,6M
QQQInvesco QQQ Trust Series 1	US$ 526,25 (0,03%)	2,36M
MLGOMicroAlgo Inc	US$ 6,3395 (-0,58%)	2,28M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Exscientia PLC (EXAI) Cours

Exscientia PLC (EXAI)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

EXAI Dernières nouvelles

Form 15-12G - Securities registration termination [Section 12(g)]

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 15-12G - Securities registration termination [Section 12(g)]

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 144 - Report of proposed sale of securities

Exscientia franchit des étapes importantes pour deux de ses programmes dans le cadre de sa collaboration avec Sanofi

EXAI - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR